Why is tacrolimus safe and recommended in lupus nephritis pregnancy while mycophenolate is contraindicated?

The decision to stop tacrolimus before conception in lupus nephritis is a medically dangerous misapplication of the correct principle that some immunosuppressants must be stopped pre-pregnancy, driven by an incorrect generalization that all immunosuppressants carry equivalent fetal risk. The nurse's task is to explain the mechanistic and regulatory distinction between a drug whose teratogenicity in humans is documented at therapeutic doses (mycophenolate) and a drug whose safety data from thousands of human pregnancies — primarily transplant recipients — does not demonstrate the same risk (tacrolimus). Tacrolimus is classified FDA Category C: animal studies have shown some adverse effects at doses above therapeutic human exposures, but human data from kidney, liver, and heart transplant pregnancies — including a U.S. National Transplantation Pregnancy Registry dataset of over a thousand tacrolimus-exposed pregnancies — show no consistent evidence of the specific structural malformation pattern associated with MMF. The primary concerns with tacrolimus in pregnancy are not teratogenicity but rather manageable pharmacological effects: neonatal hyperkalemia and renal impairment (transient, resolving within days of birth), neonatal immunosuppression (well-characterized and managed with standard neonatal infection screening protocols), and modestly increased rates of preterm birth and low birth weight (present but lower than historical cyclosporine data). None of these concerns approaches the categorical risk of MMF embryopathy. For lupus nephritis specifically, tacrolimus provides two irreplaceable functions in pregnancy: immunosuppressive T-cell suppression (through calcineurin inhibition in lymphocytes, preventing IL-2 transcription and T-cell proliferation) and direct podocyte cytoprotection (through the synaptopodin phosphorylation mechanism). Pregnancy creates uniquely adverse conditions for class V LN kidneys: GFR rises 40 to 60 percent in the second trimester as renal blood flow increases, raising intraglomerular hydrostatic pressure; the podocyte VEGF-A that normally maintains the integrity of glomerular endothelial fenestrations is diverted to placental angiogenesis; and placental factors modify the renin-angiotensin system in ways that further stress podocytes. At this moment of maximum podocyte hemodynamic stress, stopping tacrolimus removes the calcineurin inhibition that keeps synaptopodin phosphorylated and foot processes organized; the foot processes of podocytes already compromised by subepithelial immune complex deposits face both the ongoing MAC-mediated calcineurin activation and the pregnancy-induced hemodynamic amplification without CNI protection; proteinuria rises rapidly and LN flare during pregnancy is associated with a substantially increased risk of preterm birth, intrauterine growth restriction, preeclampsia superimposed on lupus nephritis, and permanent nephron loss in the mother. The EULAR 2020 recommendations on lupus nephritis and pregnancy explicitly list tacrolimus as an acceptable immunosuppressant to maintain throughout pregnancy, alongside azathioprine and HCQ. The practical management: women with class V LN who are planning pregnancy should have a preconception nephrology consultation to (1) confirm complete or partial remission on the current regimen, (2) switch MMF to azathioprine at least three months before trying to conceive (not stopping both MMF and tacrolimus — only MMF), (3) continue tacrolimus with trough monitoring more frequently in the second and third trimesters (pregnancy induces CYP3A4 and increases tacrolimus metabolism 20 to 50 percent; the trough must be monitored monthly and dose adjusted to maintain target range of 4 to 8 ng/mL), and (4) continue HCQ. The Spanish frame: 'El tacrolimus y el MMF no son equivalentes en el embarazo. El MMF puede causar malformaciones en el bebé si se toma en el primer trimestre — eso está demostrado, y por eso hay que pararlo al menos tres meses antes de intentar concebir. El tacrolimus es diferente — hay miles de embarazos de pacientes trasplantadas que tomaron tacrolimus, y no se ha visto ese patrón de malformaciones. El tacrolimus es el que protege los filtros del riñón durante el embarazo, cuando el flujo sanguíneo al riñón aumenta y los filtros están bajo más presión que en cualquier otro momento. Parar el tacrolimus justo cuando empieza el embarazo es quitarle la protección a los filtros en el momento de máximo estrés. Lo correcto es parar solo el MMF — no el tacrolimus.' (Tacrolimus and MMF are not equivalent in pregnancy. MMF can cause birth defects if taken in the first trimester — that is documented, which is why it must be stopped at least three months before trying to conceive. Tacrolimus is different — there are thousands of pregnancies of transplant patients who took tacrolimus, and that malformation pattern has not been seen. Tacrolimus is what protects the kidney filters during pregnancy, when blood flow to the kidney increases and the filters are under more pressure than at any other time. Stopping tacrolimus right when pregnancy begins removes the protection from the filters at the moment of maximum stress. The right approach is to stop only MMF — not tacrolimus.)

What is the mechanism of class V membranous lupus nephritis and how is it different from class IV lupus nephritis and primary membranous nephropathy?

Class V membranous lupus nephritis occupies a unique mechanistic position among the glomerular diseases — it shares the light microscopy and immunofluorescence appearance of primary membranous nephropathy (diffuse subepithelial immune complex deposits producing a thickened, irregular GBM with spike-and-dome pattern on silver stain and granular IgG on immunofluorescence) while being caused by the systemic autoimmune dysregulation of SLE rather than by anti-PLA2R autoantibodies against a podocyte antigen. This distinction has both diagnostic and therapeutic implications. The pathological sequence in class V LN begins with anti-dsDNA and other SLE autoantibodies forming immune complexes that deposit in the subepithelial space — between the outer surface of the glomerular basement membrane and the podocyte foot processes. The preferred location of class V immune complex deposition (subepithelial) versus class IV (subendothelial and mesangial) explains the dramatically different clinical presentations: subendothelial deposits in class IV are directly accessible to circulating complement, neutrophils, and monocytes, producing the explosive inflammatory response (crescents, wire loops, fibrinoid necrosis, RBC casts, rapidly falling GFR) characteristic of class IV; subepithelial deposits in class V are separated from the circulating complement by the GBM, so complement must diffuse across the GBM to reach the deposits, and effector cells cannot access the subepithelial space at all. The result is a more gradual pattern of injury: complement assembles C5b-9 membrane attack complexes that insert into the subepithelial aspect of podocyte membranes, directly activating the intracellular calcineurin cascade without the neutrophil-mediated destruction of capillary walls. The consequence is heavy proteinuria with preserved GFR for years to decades, in contrast to class IV where eGFR can fall by fifty percent within months. The immunofluorescence in class V LN shows granular IgG along the GBM — not the full-house polyclonal pattern of class IV — with the same distribution as primary MN. This is how class V LN is distinguished from class IV: the absence of endocapillary hypercellularity, crescents, wire loops, and full-house staining on biopsy. How class V LN is distinguished from primary MN (PLA2R-positive): class V LN typically shows concomitant mesangial immune deposits and IgA/IgM/C1q staining in addition to IgG, reflecting the polyclonal SLE autoimmunity (primary MN has IgG4-dominant staining without mesangial involvement); anti-PLA2R antibody is negative in class V LN (positive in 70 to 80 percent of primary MN); lupus serology (anti-dsDNA, ANA, low complement, anti-Sm) is positive in class V LN (absent in primary MN unless coincident). The treatment algorithm for class V LN also differs from class IV: for class IV LN, KDIGO 2021 recommends MMF 2 to 3 g/day plus glucocorticoids as the primary induction regimen, with calcineurin inhibitors as an alternative. For class V LN with nephrotic-range or escalating proteinuria (≥3.5 g/24h or rising), KDIGO 2021 recommends either (a) tacrolimus plus low-dose MMF plus glucocorticoids (the approach preferred in many Asian cohort studies where class V LN predominates and CNI-based regimens have shown high remission rates), (b) MMF monotherapy at high dose plus glucocorticoids, or (c) rituximab plus MMF. For class V LN with lower-risk proteinuria (<3.5 g/24h, stable GFR), supportive therapy with HCQ, renin-angiotensin blockade, and low-dose prednisone may be a reasonable initial approach. Class V LN co-existing with class III or IV (Class III/IV + V in the ISN/RPS classification) requires the class III/IV induction regimen for the proliferative component. The Spanish frame: 'La nefritis lúpica de clase V es distinta de la de clase IV en dónde se depositan los anticuerpos. En la clase IV, los depósitos están dentro del filtro donde el complemento y las células inflamatorias pueden atacar directamente — eso causa daño rápido con caída de la función. En la clase V, los depósitos están en la parte de afuera del filtro, donde el complemento llega pero las células inflamatorias no. Eso produce mucha proteína en la orina sin caída rápida de la función del riñón. El tratamiento usa medicamentos que protegen directamente las células del filtro — como el tacrolimus — además de suprimir el sistema inmune.' (Class V lupus nephritis is different from class IV in where the antibodies deposit. In class IV, the deposits are inside the filter where complement and inflammatory cells can attack directly — that causes rapid damage with falling function. In class V, the deposits are on the outside of the filter, where complement reaches but inflammatory cells cannot. That produces heavy protein in the urine without rapid fall in kidney function. Treatment uses medications that directly protect the filter cells — like tacrolimus — in addition to suppressing the immune system.)

What are the key Spanish phrases for tacrolimus monitoring, pregnancy planning, and class V lupus nephritis home surveillance?

For explaining tacrolimus trough monitoring and why it requires consistent timing: 'El tacrolimus es un medicamento que se tiene que tomar exactamente cada doce horas — si su horario es 8 de la mañana y 8 de la noche, hay que ser lo más constante posible con esos horarios. La razón es que el nivel en sangre sube después de tomarlo y baja antes de la próxima dosis. Cuando le hacemos el análisis de sangre para ver el nivel del tacrolimus, siempre lo hacemos justo antes de la próxima dosis — ese es el nivel mínimo, el más bajo del día, que llamamos nivel valle. Si el análisis de sangre no se hace a esa hora — si se hace dos horas después de tomar la pastilla en vez de dos horas antes — el resultado va a parecer mucho más alto de lo que realmente está en su punto más bajo, y podríamos reducir la dosis equivocadamente. Por eso: la noche antes del análisis de sangre, tome la dosis de la noche a su hora habitual, no coma ni tome nada que no sea agua desde la medianoche, venga al laboratorio por la mañana antes de tomar la dosis de la mañana, tome esa dosis inmediatamente después de que le saquen la sangre. Ese es el protocolo correcto para que el resultado refleje su nivel real.' (Tacrolimus is a medication that must be taken exactly every twelve hours — if your schedule is 8 in the morning and 8 at night, be as consistent as possible with those times. The reason is that the blood level rises after taking it and falls before the next dose. When we do the blood test to see the tacrolimus level, we always do it right before the next dose — that is the minimum level, the lowest of the day, which we call the trough level. If the blood test is not done at that time — if it is done two hours after taking the pill instead of two hours before — the result will appear much higher than it really is at its lowest point, and we might incorrectly reduce the dose. So: the night before the blood test, take the evening dose at your usual time, do not eat or drink anything except water from midnight, come to the laboratory in the morning before taking the morning dose, take that dose immediately after they draw your blood. That is the correct protocol so the result reflects your real level.) For explaining what tacrolimus side effects require a call versus what is expected: 'Algunos efectos del tacrolimus son comunes y esperados: temblores leves en las manos, hormigueo en los dedos, o dolores de cabeza ocasionales — esos son normales a niveles terapéuticos y generalmente mejoran solos con el tiempo o con un pequeño ajuste de la dosis. Háganos saber en la próxima cita. Efectos que requieren una llamada ese día: temblores fuertes o confusión mental, que podrían indicar que el nivel está demasiado alto; presión arterial muy alta que no cede; orina mucho menos de lo normal o no tiene orina en doce horas; número de potasio en sangre mayor de 5.5 en un análisis reciente (el tacrolimus puede subir el potasio). Efectos que requieren ir a urgencias ese día: fiebre alta con escalofríos (por la inmunosupresión), convulsiones, pérdida del habla o debilidad súbita en un lado del cuerpo.' (Some tacrolimus effects are common and expected: mild hand tremors, tingling in the fingers, or occasional headaches — those are normal at therapeutic levels and usually improve on their own over time or with a small dose adjustment. Let us know at the next appointment. Effects that require a call the same day: strong tremors or mental confusion, which could indicate the level is too high; very high blood pressure that does not resolve; urinating much less than normal or no urine in twelve hours; potassium above 5.5 on a recent blood test (tacrolimus can raise potassium). Effects that require going to the emergency room that day: high fever with chills (due to immunosuppression), seizures, sudden loss of speech or weakness on one side of the body.) For pre-pregnancy counseling in lupus nephritis: 'Si está pensando en quedar embarazada, hay tres pasos que tienen que ocurrir antes de que empiece a intentarlo. Primero, tiene que cambiar el MMF por azatioprina y esperar al menos tres meses — el MMF puede causar malformaciones en el bebé en el primer trimestre, y necesita ese tiempo para que el MMF salga completamente del cuerpo y para confirmar que la azatioprina le está controlando el lupus igual de bien. Segundo, tiene que hablar con nosotros para ajustar el tacrolimus — el embarazo cambia cómo el cuerpo procesa el tacrolimus, y hay que monitorear el nivel con más frecuencia durante el embarazo para que no caiga a niveles subterapeúticos. Tercero, tiene que seguir tomando el HCQ — el HCQ es el medicamento más seguro en el embarazo y es importante para proteger el corazón del bebé si usted tiene anticuerpos anti-Ro. No empiece a intentar concebir sin hablar primero con nuestro equipo.' (If you are thinking about getting pregnant, there are three steps that must happen before you start trying. First, you must switch from MMF to azathioprine and wait at least three months — MMF can cause birth defects in the first trimester, and you need that time for MMF to leave the body completely and to confirm that azathioprine is controlling lupus just as well. Second, you must talk with us to adjust tacrolimus — pregnancy changes how the body processes tacrolimus, and the level must be monitored more frequently during pregnancy so it does not fall to subtherapeutic levels. Third, you must continue taking HCQ — HCQ is the safest medication in pregnancy and is important for protecting the baby's heart if you have anti-Ro antibodies. Do not start trying to conceive without first talking to our team.) For home proteinuria monitoring in class V LN: 'Le pedimos que haga la prueba de proteína en la primera orina de la mañana una vez por semana. En la nefritis lúpica de clase V, la proteína puede subir antes de que se sienta mal — no hay síntomas precoces confiables. Si la tira reactiva sale en 1+ dos días seguidos, llámenos ese día. También llámenos si nota que los tobillos o los pies se hinchan más, que la orina se ve espumosa, o que sube de peso más de un kilo en cuarenta y ocho horas. Esas señales significan que la proteína puede estar subiendo. No espere a la próxima cita — en la nefritis lúpica, actuar rápido cuando la proteína sube puede evitar que tengamos que reiniciar el tratamiento de inducción completo.' (We ask you to do the protein test on first morning urine once a week. In class V lupus nephritis, protein can rise before you feel sick — there are no reliable early symptoms. If the test strip shows 1+ two days in a row, call us that day. Also call us if you notice that ankles or feet are swelling more, that urine looks foamy, or that you gain more than one kilogram in forty-eight hours. Those signs mean protein may be rising. Do not wait for the next appointment — in lupus nephritis, acting quickly when protein rises can prevent having to restart full induction treatment.)

Spanish for class V membranous lupus nephritis clinic nurses — the patient who stopped tacrolimus when proteinuria fell to near-normal not knowing calcineurin inhibition maintains podocyte foot processes through synaptopodin phosphorylation and stopping allows calcineurin to reactivate and proteinuria to return within weeks; the patient who stopped hydroxychloroquine when six weeks pregnant because it crosses the placenta not knowing HCQ crossing the placenta is the mechanism that reduces neonatal lupus risk and that mycophenolate — which she kept — is the proven teratogen that must be stopped; and the patient who stopped both MMF and tacrolimus before conceiving not knowing tacrolimus is safe and recommended in lupus nephritis pregnancy

The adult class V membranous lupus nephritis clinic nurse’s communication challenge

Class V lupus nephritis — membranous lupus nephritis in the ISN/RPS 2019 classification — is defined by diffuse subepithelial immune complex deposits producing heavy proteinuria without the crescentic glomerulonephritis, wire loop lesions, or rapidly progressive GFR decline of class IV disease. A patient with class V LN can carry a urine PCR of four grams per milligram and a serum albumin of 2.2 g/dL for months while her creatinine remains entirely normal, because subepithelial deposits, unlike the subendothelial deposits of class IV, are separated from circulating effector cells by the glomerular basement membrane. The therapeutic consequence is that class V LN management targets two separate processes: systemic immunosuppression (MMF, glucocorticoids) to reduce the immune complex deposition driving podocyte injury, and direct podocyte cytoprotection (tacrolimus or cyclosporine) to maintain the structural integrity of the filtration barrier while that deposition continues.

The class V LN clinic nurse works at the intersection of three distinct adherence failures, each structurally different from the adherence errors of class IV LN and each requiring its own mechanistic explanation. The first failure is stopping tacrolimus when proteinuria falls to near-normal: the patient sees a urine protein that has improved by 80 percent, concludes the kidney is recovering and the drug that was causing tremors can be stopped, and does not understand that tacrolimus-mediated calcineurin inhibition is maintaining the foot process architecture that is producing the improved protein number every day it is taken, and that stopping it removes that maintenance and allows calcineurin to reactivate and synaptopodin to dephosphorylate within days — a structural relapse that may not produce symptoms for one to four weeks but that is mechanistically inevitable from the hour of stopping. The second failure is stopping hydroxychloroquine in pregnancy because it crosses the placenta: the patient hears “crosses the placenta” and maps it to “drug exposure to the baby,” which she reasonably interprets as a risk to be avoided, not understanding that in this case the fetal exposure to HCQ is the mechanism by which it reduces the risk of neonatal lupus and anti-Ro/SSA-associated congenital complete heart block, and that the medication she has not stopped — mycophenolate — is the FDA Category D proven teratogen that must be stopped before conception. The third failure is stopping both MMF and tacrolimus before trying to conceive because a pharmacist said “immunosuppressants can harm the baby”: the patient correctly understands that MMF must stop, but incorrectly generalizes the principle to all immunosuppressants, not understanding that tacrolimus carries a completely different regulatory classification with thousands of safe human pregnancy exposures, and that stopping the CNI at the moment of maximum pregnancy-induced hemodynamic stress on an already-compromised kidney removes the only podocyte protection available at that stage.

Three conversations from the adult class V membranous lupus nephritis clinic:

Scenario 1: Adriana Castillo-Mendoza — 28 years old, San Antonio, Texas

Adriana Castillo-Mendoza was a twenty-eight-year-old pediatric medical assistant in San Antonio who had been diagnosed with SLE three years earlier after presenting with a malar rash, diffuse joint pain, and a positive ANA at 1:640 with anti-dsDNA 180 IU/mL. Her initial renal evaluation had shown a urine PCR of 0.4 mg/mg — borderline elevated but not diagnostic of active nephritis — and she was managed on hydroxychloroquine 400 mg/day with regular renal monitoring. At her two-year SLE follow-up she reported progressive bilateral ankle edema over four months, fatigue, and loss of three kilograms of lean muscle despite weight gain of two kilograms overall — the clinical pattern of hypoalbuminemia-driven edema with muscle wasting.

Labs confirmed a new nephrotic syndrome: urine PCR 4.1 mg/mg (nephrotic range); albumin 2.4 g/dL (significantly depressed; reference >3.5 g/dL); creatinine 0.8 mg/dL (still normal, consistent with class V biology); total cholesterol 312 mg/dL (nephrotic hyperlipidemia); C3 88 mg/dL (near-normal; in contrast to class IV where C3 is severely depressed); C4 18 mg/dL (normal); anti-dsDNA 120 IU/mL (moderately elevated, well below the 1,280 IU/mL of severe class IV flares); no RBC casts on microscopy (again consistent with class V, not class IV, which typically has active sediment).

Kidney biopsy was performed. Light microscopy: glomerular basement membranes with irregular thickening and a “moth-eaten” appearance on Jones silver stain; spike-and-dome pattern consistent with stage II membranous change; no endocapillary hypercellularity; no crescents; no wire loop lesions; no fibrinoid necrosis. Activity index 2/24 (minimal active inflammation); chronicity index 0/12 (no permanent damage). Immunofluorescence: granular IgG 3+ along the GBM in a peripheral capillary loop distribution; IgA 1+ and IgM 1+ in the mesangium (polyclonal staining pattern distinguishing this from primary MN which shows IgG4-dominant pure capillary loop staining); C3 2+ along GBM; C1q 1+. Electron microscopy: numerous electron-dense deposits in the subepithelial space between the outer GBM and the podocyte foot processes; foot process effacement greater than eighty percent. Anti-PLA2R antibody: negative (confirming secondary membranous nephropathy, consistent with class V LN). Diagnosis: class V pure membranous lupus nephritis, ISN/RPS 2019.

Treatment was initiated per KDIGO 2021: tacrolimus 2 mg twice daily (4 mg/day total) with target trough 5 to 8 ng/mL; mycophenolate mofetil 2 g/day (the combined tacrolimus plus MMF regimen with lower-dose glucocorticoids, preferred in class V LN with nephrotic-range proteinuria); hydroxychloroquine 400 mg/day continued; prednisone 0.5 mg/kg/day with planned slow taper; lisinopril 10 mg/day for antiproteinuric nephroprotection. Clinic nurse Carlos Vázquez-Reyes met with Adriana and her mother María at the initiation visit to explain the treatment plan, the required trough monitoring schedule, the expected side effect profile, and the duration of treatment.

The initial tacrolimus trough at week two was 6.2 ng/mL — within the target range. Adriana reported mild bilateral hand tremors, particularly noticeable when typing at work. The tremors were bothersome but not disabling; she was reassured they were expected at therapeutic troughs and typically attenuated as the trough was reached consistently. Proteinuria began declining: at month two, PCR was 2.8 mg/mg; at month four, 1.4 mg/mg; at month five, 0.9 mg/mg. Albumin had improved to 3.4 g/dL. Creatinine remained stable at 0.8 mg/dL. She felt substantially better. The edema had resolved. She had returned to normal activity.

At the month-five visit, Adriana asked about stopping tacrolimus. The tremors had not resolved fully despite being below the peak experienced at month one. She had been googling tacrolimus long-term side effects and was concerned about nephrotoxicity (ironically, a real concern at supratherapeutic troughs for prolonged durations, not at therapeutic troughs in the near-term remission induction setting). She reasoned: the protein was nearly normal, she felt well, the tremors were affecting her work quality, and she had been on tacrolimus for five months. She stopped tacrolimus four days after the visit, not waiting for a callback consultation.

She called the clinic six weeks later. The home urine dipstick, which had been negative or trace for two months, now showed 2+ protein. The scale showed a 3.1 kg gain in five weeks. Her ankles were swelling again.

Nurse Vázquez-Reyes spoke with Adriana that afternoon and explained what had happened inside the podocytes from the hour she stopped the tacrolimus. The subepithelial immune complex deposits were still there — they don’t dissolve after five months of treatment; they reduce gradually, and at five months of therapy they were still present, still activating complement at the outer GBM, still producing C5b-9 membrane attack complexes that inserted into the cytoplasmic membranes of her podocytes and elevated intracellular calcium. Calcineurin — activated by calcium-calmodulin — had been blocked every day by tacrolimus. With tacrolimus gone, calcineurin was free to act on its target.

The target was synaptopodin, an actin-associated protein found exclusively in mature podocyte foot processes that served as a structural anchor for the highly organized filamentous actin network maintaining foot process architecture. Calcineurin dephosphorylated synaptopodin at serine residues. Dephosphorylated synaptopodin was recognized and cleaved by cathepsin L, a lysosomal cysteine protease. Without phosphorylated synaptopodin bracing the actin network, the actin cytoskeleton began to transition from organized filamentous actin (F-actin) to disorganized monomeric G-actin. Foot processes widened and effaced. The slit diaphragm lost its structural support. Protein passed through the filter at an accelerating rate.

“El tacrolimus no solo suprime el sistema inmune,” Vázquez-Reyes explained. “También bloquea directamente una enzima dentro de las células del filtro del riñón que destruye la estructura que mantiene los poros sellados. Cuando la proteína llegó a 0.9, eso no significaba que el riñón se curó — significaba que el tacrolimus estaba bloqueando esa enzima cada día y manteniendo los poros en su lugar. Al parar el tacrolimus, esa enzima se activó en horas, y en unas semanas la estructura de los poros se desorganizó otra vez. El temblor es un efecto del medicamento que podemos manejar reduciendo la dosis un poco — no es señal de que el tacrolimus está dañando nada. Volvamos a empezar con 3 mg/día en lugar de 4 mg/día, y veremos si el temblor mejora mientras seguimos controlando la proteína.”

(Tacrolimus does not just suppress the immune system. It also directly blocks an enzyme inside the kidney filter cells that destroys the structure that keeps the pores sealed. When protein reached 0.9, that did not mean the kidney healed — it meant tacrolimus was blocking that enzyme every day and keeping the pores in place. By stopping tacrolimus, that enzyme activated within hours, and within a few weeks the pore structure disorganized again. The tremor is a side effect we can manage by reducing the dose a little — it is not a sign that tacrolimus is damaging anything. Let’s restart at 3 mg/day instead of 4 mg/day, and see if the tremor improves while we continue controlling the protein.)

Tacrolimus was restarted at 3 mg/day (1.5 mg twice daily). Trough at week two: 4.8 ng/mL (within the 4 to 8 ng/mL acceptable range, slightly below the preferred 5 to 8 ng/mL target). At month eight from restart: PCR 0.4 g/24h (approaching the complete remission threshold of 0.5 g/24h on 24-hour collection, or 0.3 to 0.5 mg/mg on PCR ratio). At month twelve from restart: PCR 0.28 g/24h. Albumin 3.8 g/dL. Tremors reduced substantially at 3 mg/day and had largely resolved by month three after dose reduction. Trough continued at 4.6 to 5.2 ng/mL — therapeutic and maintained. The KDIGO 2021 plan: continue tacrolimus plus MMF until at least twelve months after achieving complete remission, with gradual slow taper under nephrology supervision.

Scenario 2: Rosa María Gutiérrez-Espinoza — 32 years old, Los Angeles, California

Rosa María Gutiérrez-Espinoza was a thirty-two-year-old licensed vocational nurse in Los Angeles who had been diagnosed with SLE five years earlier and class V membranous lupus nephritis two years earlier. Her LN history: initial presentation with PCR 3.8 mg/mg, creatinine 0.7 mg/dL, albumin 2.6 g/dL, mild ankle edema, C3 82 mg/dL (normal), anti-dsDNA 95 IU/mL (mildly elevated), anti-Ro/SSA positive at 240 U/mL (high); biopsy class V membranous LN, activity index 1/24, chronicity index 0/12. She was anti-PLA2R negative. Treatment: tacrolimus 4 mg/day target trough 5 to 8 ng/mL, MMF 1.5 g/day, HCQ 400 mg/day, prednisone 0.5 mg/kg/day with taper. Complete remission achieved at month ten (PCR 0.22 mg/mg, albumin 4.0 g/dL, creatinine 0.7 mg/dL). Maintenance continued: tacrolimus 2 mg/day (trough 4.2 ng/mL, stable), MMF 1.5 g/day, HCQ 400 mg/day.

At her two-year maintenance visit, Rosa reported that she and her husband Eduardo had been trying to conceive. Her last menstrual period had been six weeks prior. A home pregnancy test that morning was positive. She had not yet had prenatal confirmation but the test was strongly positive.

The clinic team was glad to hear this and immediately scheduled an urgent prenatal-LN-planning visit for the next day — a visit that should have happened pre-conception. Rosa mentioned that before coming in, she had told her coworker María (a nurse in the labor and delivery unit) about the pregnancy. María had told Rosa immediately that hydroxychloroquine was known to cross the placenta, that the fetus would be exposed to the drug, and that Rosa should stop it right away and call her rheumatologist. Rosa had stopped HCQ that morning. She was still taking MMF and tacrolimus.

At the urgent visit, clinic nurse Elena Torres-Fonseca addressed the medication question before anything else. She confirmed that Rosa had stopped HCQ and that she was currently at six weeks gestation. She then explained the two critically important facts that reversed the logic of Rosa’s coworker’s advice.

The first fact was about HCQ and placental crossing. It was entirely true that HCQ crossed the placenta — it had a long half-life (approximately 50 days in maternal tissue), accumulated in multiple tissue compartments, and was measurable in fetal cord blood at delivery. This was not a reason to stop it. The reason it crossed the placenta was the same reason it protected the fetus: TLR7 and TLR9 inhibition in plasmacytoid dendritic cells. Rosa had a high-positive anti-Ro/SSA antibody at 240 U/mL. Anti-Ro/SSA IgG crossed the placenta during weeks 12 to 24 of gestation and could deposit in the fetal A-V node during the critical window of fetal cardiac conduction system development. In anti-Ro/SSA-positive mothers, the risk of neonatal complete congenital heart block (permanent, requiring a pacemaker) was approximately 2 percent for a first pregnancy and 15 to 20 percent for subsequent pregnancies if a prior child had been affected. The pathway was amplifiable: anti-Ro/SSA IgG formed immune complexes with Ro52/Ro60 ribonucleoproteins from apoptotic maternal cells, which were taken up by maternal and placental pDCs; TLR7 and TLR9 in those pDCs, in an acidic endolysosomal environment, recognized the RNA and DNA components of the Ro ribonucleoprotein complexes; the MyD88 → IRAK4 → IRF7 → IFN-alpha cascade massively amplified anti-Ro/SSA antibody production from B cells stimulated by the pDC-derived interferon; more anti-Ro/SSA IgG crossed the placenta; more deposited in the fetal A-V node. HCQ raised the endolysosomal pH in those pDCs — the same mechanism by which it reduced renal pDC interferon signaling in lupus nephritis — blocking TLR7 and TLR9 activation at the maternal-fetal interface, reducing the IFN-alpha amplification of anti-Ro/SSA production, and lowering the burden of anti-Ro/SSA IgG available for placental transfer. Multiple prospective studies, including the PRIDE cohort and the work of Jaeggi et al., had demonstrated that anti-Ro/SSA-positive mothers who continued HCQ throughout pregnancy had lower rates of neonatal heart block. The EULAR 2020 recommendations on SLE and pregnancy stated explicitly: “HCQ should be continued throughout pregnancy.” The ACR 2020 guidelines on reproductive health in rheumatic disease stated: “We strongly recommend that HCQ be continued in women with SLE who are pregnant or planning pregnancy.”

Additionally, stopping HCQ during pregnancy tripled the maternal risk of lupus flare. A lupus flare in pregnancy — including a class V LN flare — was associated with preterm birth, intrauterine growth restriction, and superimposed preeclampsia, all carrying higher fetal and maternal risk than continued HCQ exposure.

“El HCQ cruza la placenta porque eso es exactamente lo que necesita hacer para proteger el corazón del bebé,” Torres-Fonseca said. “Sus anticuerpos anti-Ro son muy altos — 240 unidades. Esos anticuerpos también cruzan la placenta, y si no los controlamos, hay un riesgo real de que afecten el sistema de conducción del corazón del bebé durante las semanas 18 a 24. El HCQ bloquea la señal que amplifica esos anticuerpos en la placenta. Parar el HCQ le quita esa protección al bebé y también triplica su riesgo de brote de lupus durante el embarazo. Tiene que volver a tomar el HCQ hoy — eso es urgente.”

(HCQ crosses the placenta because that is exactly what it needs to do to protect the baby’s heart. Your anti-Ro antibodies are very high — 240 units. Those antibodies also cross the placenta, and if we do not control them, there is a real risk they will affect the baby’s cardiac conduction system during weeks 18 to 24. HCQ blocks the signal that amplifies those antibodies in the placenta. Stopping HCQ removes that protection for the baby and also triples your risk of lupus flare during pregnancy. You must restart HCQ today — that is urgent.)

The second fact was about MMF. Rosa was still on MMF 1.5 g/day at six weeks pregnant. Mycophenolate mofetil was FDA Category D. The teratogenic mechanism was well-characterized: MMF inhibited IMPDH in rapidly dividing cells, and rapidly dividing embryonic cells during organogenesis at weeks 6 to 12 were among the most sensitive; the resulting nucleotide depletion produced MMF embryopathy — a recognized syndrome of external ear abnormalities (microtia, atresia of the external auditory canal), cleft lip and palate, micrognathia, hypertelorism, limb hypoplasia, and congenital heart defects, at a malformation rate of approximately 22 to 26 percent in the first trimester in transplant registry data. EULAR and ACR guidelines recommended that MMF be stopped at least three months before attempting conception — a step that had not occurred here because the pregnancy was not planned pre-conception. At six weeks, organogenesis was ongoing. The priority was to stop MMF immediately and switch to azathioprine.

Torres-Fonseca explained: azathioprine 1.5 mg/kg/day (75 mg/day for Rosa at 50 kg) was FDA Category D by labeling (an artifact of its early animal study data at high doses), but decades of safety data from SLE and organ transplant pregnancies, including the national pregnancy registries, did not demonstrate the specific pattern of structural malformations associated with MMF. Azathioprine was the standard-of-care immunosuppressant for maintaining SLE and LN remission during pregnancy. Rosa’s tacrolimus — which she was already on — should continue; it was classified FDA Category C and was the recommended CNI for pregnancy in LN, providing both immunosuppression and direct podocyte cytoprotection.

Rosa restarted HCQ that day. MMF was stopped immediately and azathioprine 75 mg/day initiated. Tacrolimus 2 mg/day continued with monthly trough monitoring (target 4 to 8 ng/mL; trough was monitored more frequently given pregnancy-induced CYP3A4 upregulation that would begin to lower tacrolimus levels in the second trimester). At a repeat visit at ten weeks with fetal heartbeat confirmed on ultrasound, all labs were stable: PCR 0.24 mg/mg (maintained remission), creatinine 0.7 mg/dL, albumin 3.9 g/dL, C3 91 mg/dL, anti-dsDNA 78 IU/mL. Rosa delivered at 38 weeks. Birth weight 3.1 kg. Fetal cardiac screening at delivery and one-week follow-up: normal sinus rhythm, no conduction abnormalities. Six-month infant follow-up: no neonatal lupus signs (no skin rash, no heart block). Anti-Ro/SSA screen on cord blood: positive (expected, transient maternal antibody transfer), cleared at four months of age.

Scenario 3: Valentina Moreno-Salinas — 35 years old, Houston, Texas

Valentina Moreno-Salinas was a thirty-five-year-old bilingual hospital unit secretary in Houston who had been diagnosed with SLE four years earlier and class V membranous lupus nephritis twenty-two months earlier. Her LN history: initial presentation with PCR 4.8 mg/mg, creatinine 0.7 mg/dL, albumin 2.1 g/dL, cholesterol 348 mg/dL; biopsy class V, activity index 3/24, chronicity index 0/12; anti-PLA2R negative; anti-Ro/SSA weakly positive at 42 U/mL; anti-dsDNA 88 IU/mL. Treatment: tacrolimus 4 mg/day (trough target 5 to 8 ng/mL), MMF 2 g/day, HCQ 400 mg/day, prednisone taper. Complete remission at month fourteen: PCR 0.28 mg/mg, albumin 4.1 g/dL, creatinine 0.7 mg/dL, anti-dsDNA 42 IU/mL. Maintenance: tacrolimus 4 mg/day (trough 5.8 ng/mL), MMF 2 g/day, HCQ 400 mg/day, prednisone weaned to 0.

At the twenty-two-month maintenance visit, Valentina told her rheumatologist that she and her husband Manuel wanted to try to conceive. Her rheumatologist reviewed the preconception protocol: the critical step was to stop MMF at least three months before attempting conception and switch to azathioprine, because MMF was a teratogen. Valentina was instructed to return in three months on azathioprine for pre-conception clearance. She was given a prescription for azathioprine 100 mg/day (approximately 1.5 mg/kg at 66 kg), and the visit ended with the instruction to come back in three months.

On her way home, Valentina stopped at her local pharmacy to fill the azathioprine prescription. While there, she asked the pharmacist — a general community pharmacist without specific LN expertise — about whether she should continue taking tacrolimus during pregnancy as well, since she had read it was also an immunosuppressant. The pharmacist told her that immunosuppressants were generally dangerous in pregnancy and that both MMF and tacrolimus suppressed the immune system, so if she was planning pregnancy she should probably stop both. Valentina stopped tacrolimus that evening along with MMF. She started azathioprine as prescribed and continued HCQ and her lisinopril (which she later stopped as well when she discovered it was contraindicated in pregnancy — correctly, as ACE inhibitors are FDA Category D contraindicated in the second and third trimesters).

She did not call her rheumatologist or nephrologist at any of these stopping decisions — she felt she was following her rheumatologist’s advice (stop immunosuppressants, start azathioprine) and the pharmacist’s additional counsel (stop tacrolimus too). Three months after stopping MMF and tacrolimus, she began trying to conceive. She conceived in the first month. At the ten-week obstetric visit, her urine dipstick was 3+ protein. She was referred back to nephrology urgently.

At the ten-week nephrology visit, labs confirmed a class V LN flare: PCR 2.8 mg/mg (from her stable 0.28 mg/mg); albumin 2.8 g/dL (from 4.1 g/dL); creatinine 0.9 mg/dL (from 0.7 mg/dL, a 29 percent rise that in the context of ten weeks of pregnancy — when GFR should be rising, not falling — was ominous). Blood pressure 142/90 mmHg (she was off lisinopril correctly per obstetric guidance, but the blood pressure rise required a safe antihypertensive in pregnancy: labetalol was started). A flare at ten weeks of pregnancy, with creatinine rising and albumin falling, carried a substantially elevated risk of superimposed preeclampsia (which occurs at higher rates in women with proteinuric renal disease), preterm birth, intrauterine growth restriction, and permanent nephron loss from the flare episode itself.

Clinic nurse Alejandra Cisneros-Herrera met with Valentina and Manuel urgently. Manuel was confused: the rheumatologist had told them to stop MMF, the pharmacist had told them to stop tacrolimus, and they had followed the advice they were given. Why was stopping tacrolimus dangerous?

Nurse Cisneros-Herrera acknowledged the confusion directly. The advice from the rheumatologist had been correct: stop MMF. The advice from the pharmacist had been wrong, because it applied a true principle — some immunosuppressants are dangerous in pregnancy — to a drug for which the specific evidence was the opposite of the general principle. Tacrolimus and MMF were both immunosuppressants, but they had completely different pregnancy safety profiles. MMF caused structural malformations of the embryo at therapeutic doses, with a documented 22 to 26 percent malformation rate in transplant registry first-trimester data. Tacrolimus had been used in thousands of kidney, liver, and heart transplant pregnancies in the United States and internationally; no consistent pattern of structural malformations had been found; the teratogenicity concern that drove the FDA Category C classification was based on animal studies at supratherapeutic doses, not on human registry data. Tacrolimus was on the EULAR and ACR recommended medication lists for maintaining LN remission throughout pregnancy. Azathioprine was also recommended, and azathioprine alone was what Valentina was on now. But azathioprine, while safe in pregnancy, was an immunosuppressant targeting lymphocyte proliferation through TPMT-mediated antimetabolite synthesis — it did not have the direct podocyte cytoprotective effect of calcineurin inhibition. In class V LN, where the primary mechanism of proteinuria was calcineurin-mediated synaptopodin dephosphorylation driven by subepithelial MAC deposition, azathioprine protected the immune compartment but did not protect the foot processes. Tacrolimus protected the foot processes. Both were needed.

Moreover, Valentina’s pregnancy itself was now creating the worst possible hemodynamic conditions for her unprotected podocytes. GFR rises 40 to 60 percent in the second trimester as renal blood flow increases driven by a combination of hormonal vasodilation (progesterone, relaxin), increased cardiac output, and expanded circulating volume. This hyperfiltration increased the mechanical stress on every glomerulus. In a healthy pregnancy, podocytes adapted to this hemodynamic change through VEGF-A-mediated glomerular endothelial fenestration expansion and structural foot process changes. In a class V LN kidney — where subepithelial immune complex deposits were still present, C5b-9 was still inserting into podocyte membranes, calcineurin was still being activated, and tacrolimus was no longer present to block it — the hyperfiltration added to the MAC-mediated calcineurin-synaptopodin disruption, compounding foot process effacement and proteinuria. Without CNI protection, the podocytes faced two simultaneous insults where they would otherwise face one.

“El tacrolimus no es como el MMF,” Cisneros-Herrera said. “El MMF puede causar malformaciones en el bebé — eso está documentado. El tacrolimus es diferente: hay miles de embarazos de pacientes trasplantadas que han tomado tacrolimus durante todo el embarazo, y no se ha visto ese patrón de malformaciones. Las guías médicas dicen que el tacrolimus es seguro durante el embarazo. Pero hay algo más: el tacrolimus no solo suprime el sistema inmune. También protege directamente las células del filtro del riñón bloqueando una enzima que las destruye. El embarazo pone más presión en esos filtros que en cualquier otro momento. Sin el tacrolimus, esa enzima está activa, los filtros se dañan, y la proteína sube. Necesitamos reiniciar el tacrolimus hoy para proteger su riñón y el bebé.”

(Tacrolimus is not like MMF. MMF can cause birth defects in the baby — that is documented. Tacrolimus is different: there are thousands of pregnancies of transplant patients who took tacrolimus throughout pregnancy, and that malformation pattern has not been seen. Medical guidelines say tacrolimus is safe during pregnancy. But there is something else: tacrolimus does not only suppress the immune system. It also directly protects the kidney filter cells by blocking an enzyme that destroys them. Pregnancy puts more pressure on those filters than at any other time. Without tacrolimus, that enzyme is active, the filters are damaged, and protein rises. We need to restart tacrolimus today to protect your kidney and the baby.)

Tacrolimus was restarted at 3 mg/day. Given pregnancy-induced CYP3A4 upregulation, trough monitoring was scheduled weekly for the first month (CYP3A4 activity increases progressively in pregnancy, raising tacrolimus clearance and lowering trough; dose adjustment every one to two weeks may be required, with doses increasing by 50 to 100 percent of pre-pregnancy dose common by the third trimester). At two weeks: trough 3.8 ng/mL (low; dose increased to 4 mg/day). At four weeks: trough 5.2 ng/mL (therapeutic). At twelve weeks of pregnancy: PCR had begun declining from 2.8 to 1.9 mg/mg. Albumin 3.1 g/dL (recovering). Creatinine 0.8 mg/dL (stable). At twenty weeks: PCR 0.9 mg/mg; albumin 3.6 g/dL. At delivery (37 weeks + 4 days, late preterm induced for borderline IUGR on growth scan at 36 weeks): PCR 0.48 mg/mg; albumin 3.4 g/dL; birth weight 2.6 kg. At the six-week postpartum nephrology visit: creatinine 0.9 mg/dL; eGFR 64 mL/min/1.73m² (down from her pre-pregnancy eGFR of 86 mL/min/1.73m² — a permanent 26 percent reduction in GFR from the ten-week unprotected flare, representing nephron loss that could not be recovered). The baby was healthy; no neonatal lupus signs; weakly positive anti-Ro/SSA on cord blood (expected, cleared at five months). Tacrolimus dose reduced back to 3 mg/day at six weeks postpartum (CYP3A4 induction resolves within weeks of delivery; dose requires careful downward adjustment to avoid supratherapeutic levels in the postpartum period).

Frequently asked questions

Why must tacrolimus continue in class V lupus nephritis even after proteinuria falls to near-normal?

Near-normal proteinuria in class V LN under tacrolimus treatment reflects the drug actively maintaining synaptopodin phosphorylation in podocytes, not the permanent resolution of subepithelial immune complex disease. Tacrolimus binds FKBP12 to inhibit calcineurin (PP2B), the calcium-calmodulin-dependent phosphatase that dephosphorylates synaptopodin in podocytes. Subepithelial C5b-9 membrane attack complex insertion elevates podocyte intracellular calcium, activating calcineurin to dephosphorylate synaptopodin; dephosphorylated synaptopodin is cleaved by cathepsin L; the actin cytoskeleton collapses from organized F-actin to disorganized G-actin; foot processes efface; proteinuria rises. Tacrolimus blocks calcineurin, keeping synaptopodin phosphorylated, foot processes organized, and proteinuria low. Stopping tacrolimus removes this calcineurin inhibition within hours; synaptopodin dephosphorylation begins within one to two days; foot process effacement resumes within one to four weeks; proteinuria rises. The subepithelial deposits that drive MAC-mediated calcineurin activation do not dissolve in five months of treatment; they reduce gradually over twelve to eighteen months of combined tacrolimus plus MMF. KDIGO 2021 recommends continuing tacrolimus plus MMF for at least twelve months after achieving complete remission in class V LN. The tremors and other tacrolimus side effects are dose-dependent and manageable through trough-guided dose reduction — they are not a signal to stop. The Spanish frame: “La proteína baja no significa que el riñón se curó — significa que el tacrolimus está manteniendo la estructura de los filtros cada día. Al parar el tacrolimus, esa estructura se desorganiza en días y la proteína vuelve en semanas. El plan correcto es seguir con el tacrolimus y ajustar la dosis para reducir el temblor, no pararlo.” (Low protein does not mean the kidney healed — it means tacrolimus is maintaining the filter structure every day. By stopping tacrolimus, that structure disorganizes in days and protein returns in weeks. The right plan is to continue tacrolimus and adjust the dose to reduce the tremor, not stop it.)

Why must hydroxychloroquine continue in lupus nephritis pregnancy and why is mycophenolate the teratogen requiring urgent switch?

HCQ crossing the placenta is the mechanism of neonatal lupus prevention, not a teratogenicity risk. In anti-Ro/SSA-positive mothers, anti-Ro/SSA IgG forms immune complexes with Ro ribonucleoproteins; those complexes are taken up by maternal and placental pDCs; TLR7 and TLR9 in those pDCs (in acidic endolysosomes) amplify anti-Ro/SSA production via MyD88-IRF7-IFN-alpha; more anti-Ro/SSA IgG crosses the placenta to the fetal A-V node. HCQ raises endolysosomal pH in maternal and placental pDCs, blocking TLR7/9 activation and reducing the IFN-alpha amplification of anti-Ro/SSA production. Multiple prospective studies confirm lower neonatal heart block rates with continued HCQ. Additionally, stopping HCQ triples maternal LN flare risk during pregnancy. MMF, by contrast, is FDA Category D with documented MMF embryopathy (external ear malformations, cleft lip/palate, micrognathia, congenital heart defects) at an approximately 22 to 26 percent malformation rate in first-trimester transplant data. MMF must be stopped at least three months before conception; azathioprine (compatible with pregnancy) or tacrolimus (FDA Category C, safe in thousands of transplant pregnancies) replaces MMF. EULAR 2020 and ACR 2020 both recommend: continue HCQ throughout pregnancy; switch MMF to azathioprine at least 3 months pre-conception; continue tacrolimus or switch to tacrolimus if not already on it. The Spanish frame: “El HCQ es el único medicamento que protege el corazón del bebé de los anticuerpos anti-Ro. Tiene que seguir tomándolo. El MMF sí puede causar malformaciones — ese es el que hay que parar tres meses antes. El tacrolimus es seguro en el embarazo y lo continuamos.” (HCQ is the only medication that protects the baby’s heart from anti-Ro antibodies. You must continue taking it. MMF can cause birth defects — that is the one that must be stopped three months before. Tacrolimus is safe in pregnancy and we continue it.)

Why is tacrolimus the recommended calcineurin inhibitor in lupus nephritis pregnancy while mycophenolate is contraindicated?

The distinction between tacrolimus (FDA Category C, recommended in LN pregnancy) and mycophenolate (FDA Category D, contraindicated in pregnancy) is absolute and not a matter of degree. MMF causes MMF embryopathy through IMPDH inhibition in rapidly dividing embryonic cells during organogenesis, producing a specific and documented malformation pattern with a 22 to 26 percent rate in first-trimester human pregnancy data. Tacrolimus has been used in thousands of kidney, liver, and heart transplant pregnancies; no consistent structural malformation pattern has been identified; the FDA Category C classification reflects animal-study data at supratherapeutic doses, not human evidence of teratogenicity. EULAR 2020 and ACR 2020 explicitly list tacrolimus as acceptable throughout pregnancy in LN. Tacrolimus provides both immunosuppressive (T-cell IL-2 inhibition) and direct podocyte cytoprotective (calcineurin inhibition → synaptopodin phosphorylation maintained) functions in class V LN. Pregnancy increases hemodynamic stress on glomeruli (40 to 60 percent GFR rise in the second trimester) and increases tacrolimus metabolism (CYP3A4 induction raises clearance; dose may need to increase 50 to 100 percent to maintain therapeutic trough; weekly monitoring recommended). Stopping tacrolimus pre-conception in class V LN removes podocyte CNI protection at the moment of maximum hemodynamic stress; the resulting flare is associated with preterm birth, IUGR, superimposed preeclampsia, and permanent nephron loss. The correct pre-conception protocol: stop only MMF (switch to azathioprine); continue tacrolimus; continue HCQ; pre-conception nephrology consult to confirm remission and review trough monitoring frequency during pregnancy. The Spanish frame: “El MMF y el tacrolimus no son iguales en el embarazo. El MMF puede causar malformaciones documentadas. El tacrolimus es seguro según miles de embarazos de pacientes trasplantadas. Al planear el embarazo, paramos solo el MMF y lo cambiamos por azatioprina — el tacrolimus y el HCQ se continúan.” (MMF and tacrolimus are not equal in pregnancy. MMF can cause documented malformations. Tacrolimus is safe according to thousands of pregnancies of transplant patients. When planning pregnancy, we stop only MMF and replace it with azathioprine — tacrolimus and HCQ are continued.)

What is the mechanism of class V lupus nephritis and how does it differ from class IV LN and primary membranous nephropathy?

Class V LN is secondary membranous nephropathy caused by SLE autoimmune dysregulation producing immune complex deposition in the subepithelial space between the outer GBM and podocyte foot processes. Unlike class IV LN (subendothelial and mesangial deposits directly activating circulating complement and effector cells, producing crescents, wire loops, fibrinoid necrosis, and rapid GFR decline), class V subepithelial deposits are separated from the circulation by the GBM: complement must cross the GBM to reach the deposits, and effector cells cannot access the subepithelial space, producing a slower pattern of MAC-mediated podocyte injury without the explosive inflammatory response of class IV. The clinical consequence: heavy nephrotic-range proteinuria with preserved GFR for years, in contrast to class IV where GFR can decline 50 percent within months. Light microscopy: thickened, irregular GBM with spike-and-dome pattern on silver stain; no endocapillary hypercellularity, crescents, or wire loops. Immunofluorescence: granular IgG along GBM plus mesangial IgA/IgM/C1q (polyclonal SLE pattern, distinguishing from primary MN which shows IgG4-dominant pure capillary loop staining). Electron microscopy: subepithelial electron-dense deposits with overlying GBM spikes; foot process effacement. Anti-PLA2R antibody: negative in class V LN (positive in 70 to 80 percent of primary MN). Complement: near-normal or mildly depressed in pure class V LN (in contrast to severely depressed C3/C4 in class IV). Treatment: CNI (tacrolimus) plus low-dose MMF plus HCQ for nephrotic-range proteinuria per KDIGO 2021, with direct podocyte CNI cytoprotection supplementing immunosuppression. The Spanish frame: “En la nefritis lúpica de clase V, los depósitos están en el exterior del filtro, donde producen daño directo en las células del filtro pero sin la inflamación explosiva de la clase IV. Eso es por qué la función del riñón puede estar bien durante mucho tiempo aunque haya mucha proteína en la orina. El tacrolimus protege esas células del filtro directamente además de suprimir el sistema inmune.” (In class V lupus nephritis, the deposits are on the outside of the filter, where they cause direct damage to the filter cells but without the explosive inflammation of class IV. That is why kidney function can be normal for a long time even with heavy protein in the urine. Tacrolimus directly protects those filter cells in addition to suppressing the immune system.)

What are the key Spanish phrases for tacrolimus monitoring, pregnancy planning, and home proteinuria surveillance in class V lupus nephritis?

For tacrolimus trough monitoring and correct timing: “El tacrolimus se toma cada doce horas y el nivel en sangre tiene que medirse justo antes de la próxima dosis — ese es el nivel mínimo correcto. Si la muestra se saca después de tomar la pastilla, el resultado va a parecer falso alto y podríamos reducir la dosis por error. Para el análisis: noche anterior, tome la dosis de noche a su hora habitual. Ayune desde la medianoche. Venga al laboratorio por la mañana antes de tomar la dosis de la mañana. Tome la dosis inmediatamente después del análisis.” (Tacrolimus is taken every twelve hours and the blood level must be measured right before the next dose — that is the correct minimum level. If the sample is taken after the pill, the result will appear falsely high and we could reduce the dose by mistake. For the test: previous night, take the evening dose at your usual time. Fast from midnight. Come to the laboratory in the morning before taking the morning dose. Take the dose immediately after the test.) For pre-pregnancy counseling: “Antes de intentar quedar embarazada, necesitamos: parar el MMF y cambiarlo por azatioprina al menos tres meses antes — el MMF puede causar malformaciones en el primer trimestre; continuar el tacrolimus durante el embarazo — es seguro y protege el riñón cuando la sangre al riñón aumenta en el embarazo; continuar el HCQ — protege el corazón del bebé si tiene anticuerpos anti-Ro; monitorear el nivel de tacrolimus con más frecuencia durante el embarazo porque el embarazo cambia cómo el cuerpo procesa el medicamento. No empiece a intentar concebir sin llamarnos primero.” (Before trying to get pregnant, we need: to stop MMF and replace it with azathioprine at least three months before — MMF can cause birth defects in the first trimester; to continue tacrolimus during pregnancy — it is safe and protects the kidney when blood flow to the kidney increases in pregnancy; to continue HCQ — it protects the baby’s heart if you have anti-Ro antibodies; to monitor tacrolimus levels more frequently during pregnancy because pregnancy changes how the body processes the medication. Do not start trying to conceive without calling us first.) For home proteinuria monitoring in class V LN: “Le pedimos que haga la prueba de proteína en la primera orina de la mañana una vez por semana. Si la tira reactiva marca 1+ dos días seguidos, llámenos ese día. También llámenos si nota tobillos hinchados, aumento rápido de peso, orina espumosa, o párpados hinchados por la mañana. En la nefritis lúpica de clase V, la función del riñón puede estar normal incluso cuando la proteína está muy alta — por eso la tira de orina en casa es la señal de alarma más sensible que tenemos. Entre más rápido actuamos cuando la proteína sube, menos daño permanente queda.” (We ask you to do the protein test on first morning urine once a week. If the test strip shows 1+ two days in a row, call us that day. Also call us if you notice swollen ankles, rapid weight gain, foamy urine, or puffy eyelids in the morning. In class V lupus nephritis, kidney function can be normal even when protein is very high — that is why the home urine strip is the most sensitive alarm signal we have. The faster we act when protein rises, the less permanent damage remains.)